May, 2006
No. 91 (5)

Articles

The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model

E Menu, K Asosingh, S Indraccolo, H De Raeve, I Van Riet, E Van Valckenborgh, I Van de Broek, N Fujii, H Tamamura, B Van Camp, K Vanderkerken

https://doi.org/10.3324/%25x

The mechanisms of vitamin K2-induced apoptosis of myeloma cells

T Tsujioka, Y Miura, T Otsuki, Y Nishimura, F Hyodoh, H Wada, T Sugihara

https://doi.org/10.3324/%25x

Mutations in telomerase catalytic protein in Japanese children with aplastic anemia

J Liang, H Yagasaki, Y Kamachi, A Hama, K Matsumoto, K Kato, K Kudo, S Kojima

https://doi.org/10.3324/%25x

Minimal residual disease analysis in children with t(12;21)-positive acute lymphoblastic leukemia: comparison of Ig/TCR rearrangements and the genomic fusion gene

M Metzler, G Mann, U Monschein, M Lodzinski, C Gall, T Flohr, S Viehmann, T Langer, M Schrappe, H Gadner, OA Haas, ER Panzer-Grumayer

https://doi.org/10.3324/%25x

Letters to the Editor

Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma

N Mounier, J Briere, C Gisselbrecht, F Reyes, P Gaulard, B Coiffier, Groupe d'Etude des Lymphomes de l'Adulte

https://doi.org/10.3324/%25x

Case Reports

TERC mutations in children with refractory cytopenia

CA Ortmann, CM Niemeyer, A Wawer, W Ebell, I Baumann, CP Kratz

https://doi.org/10.3324/%25x

Comparative Studies

Clinical Trial

Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study

J de la Rubia, J Blade, JJ Lahuerta, JM Ribera, R Martinez, A Alegre, J Garcia-Larana, P Fernandez, A Sureda, F de Arriba, D Carrera, J Besalduch, R Garcia Boyero, L Palomera Bernal, MT Hernandez, PR Garcia, J Perez-Calvo, A Alcala, LF Casado, J San Miguel

https://doi.org/10.3324/%25x

Biography

Evaluation Studies

Clinical Trial, Phase II

Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes

PA Broliden, IM Dahl, R Hast, B Johansson, E Juvonen, L Kjeldsen, A Porwit-MacDonald, M Sjoo, JM Tangen, B Uggla, G Oberg, E Hellstrom-Lindberg

https://doi.org/10.3324/%25x

Comments